Genprex Stock (NASDAQ:GNPX)


OwnershipFinancialsChart

Previous Close

$0.64

52W Range

$0.62 - $55.00

50D Avg

$0.96

200D Avg

$4.25

Market Cap

$1.07M

Avg Vol (3M)

$617.27K

Beta

-0.96

Div Yield

-

GNPX Company Profile


Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

15

IPO Date

Mar 29, 2018

Website

GNPX Performance


GNPX Financial Summary


Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-21.17M$-31.08M
Net Income$-16.23M$-21.11M$-30.86M
EBITDA-$-21.10M$-31.06M
Basic EPS$-17.40$-266.95$-1.13K
Diluted EPS$-17.40$-266.95$-1.13K

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison


TickerCompany
LIMNLiminatus Pharma, Inc. Class A Common Stock
BDRXBiodexa Pharmaceuticals Plc
GRIGRI Bio, Inc.
JAGXJaguar Health, Inc.
INMInMed Pharmaceuticals Inc.
CNSPCNS Pharmaceuticals, Inc.
CEROCERo Therapeutics Holdings, Inc.
CMMBChemomab Therapeutics Ltd.
BIVIBioVie Inc.